Dako collaborates with Genentech on cancer therapy
Dako, a Danish provider of cancer diagnostic solutions, has signed an agreement with Genentech, a US-based biotechnology company, for a drug-companion diagnostic co-development programme for a targeted cancer therapy.
Dako, a Danish provider of cancer diagnostic solutions, has signed an agreement with Genentech, a US-based biotechnology company, for a drug-companion diagnostic co-development programme for a targeted cancer therapy.
The collaboration will use Dako's experience in developing cancer diagnostic tests to identify cancer patients who may receive greater benefits from a certain therapy.
Under the terms of the agreement, the two companies will collaborate on developing a new cancer diagnostic test as a potential companion product for a specific Genentech investigational therapeutic.
The collaboration is in line with Dako's ongoing strategy to combine its strengths with biotechnology and pharmaceutical companies to develop its pharmacodiagnostic assays.
"We are very pleased to announce our collaboration with Genentech to potentially further expand the market for targeted therapies. We see a great potential in a strong collaborative approach between biotechnology and pharmaceutical companies and diagnostic companies in targeting the right drugs for the right patients, both to improve patient care and more efficiently managing healthcare costs," said Patrik Dahlen, ceo and president of Dako Denmark.
"We believe the new collaboration with Genentech recognizes Dako's position in the clinical diagnostics market and as a strong partner for developing diagnostic tests for use in conjunction with drug therapies."